🇺🇸 Enfortumab Vedotin-Ejfv in United States

320 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Death — 38 reports (11.88%)
  2. Fatigue — 38 reports (11.88%)
  3. Inappropriate Schedule Of Product Administration — 35 reports (10.94%)
  4. Rash — 34 reports (10.62%)
  5. Diarrhoea — 33 reports (10.31%)
  6. Nausea — 32 reports (10%)
  7. Neuropathy Peripheral — 32 reports (10%)
  8. Decreased Appetite — 31 reports (9.69%)
  9. Pruritus — 24 reports (7.5%)
  10. Alopecia — 23 reports (7.19%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Enfortumab Vedotin-Ejfv approved in United States?

Enfortumab Vedotin-Ejfv does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Enfortumab Vedotin-Ejfv in United States?

Mirati Therapeutics Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.